Example: Heart Attack

Clinical Trials on Glabellar Crease

Total 10000 results

NCT03330847

Active, not recruiting

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Metastatic Triple Negative Breast Cancer
NCT05520723

Completed

Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED (PRIMED)

Breast Cancer | Triple Negative Breast Cancer | Advanced HR+/HER2- Breast Cancer
NCT04395989

Active, not recruiting

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. (FUTURE-SUPER)

TNBC - Triple-Negative Breast Cancer
NCT02834403

Completed

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Metastatic Triple Negative Breast Cancer
NCT01676753

Completed

Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer

Triple Negative Breast Cancer | Advanced or Metastatic Breast Cancer
NCT02719691

Completed

Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer

Metastatic Breast Cancer | Solid Tumors
NCT03254654

Completed

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

Advanced Triple-Negative Breast Cancer
NCT04149444

Withdrawn

A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer (TACTIC)

Metastatic Triple Negative Breast Cancer
NCT01672671

Completed

BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy

Early Triple Negative Breast Cancer
NCT07017673

Recruiting

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

TNBC - Triple-Negative Breast Cancer | TNBC | Early Stage Triple-Negative Breast Carcinoma
NCT03285568

Completed

Patterns of Prescribing and Monitoring of Palbociclib

Advanced Breast Cancer | Metastatic Breast Cancer | Estrogen Receptor-positive Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
NCT04262518

Unknown

Feasibility of Integrating the Outcomes4Me Smartphone Navigation Application Into the Care Management of Breast Cancer Patients (FIONA)

Breast Cancer | Metastatic Breast Cancer | Breast Carcinoma | Invasive Breast Cancer | Metastatic Breast Carcinoma
NCT03251378

Completed

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

Rectal Cancer | Advanced Solid Tumors | Metastatic Breast Cancer | Triple Negative Breast Cancer | Metastatic Colon Cancer | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer
NCT03853707

Completed

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma
NCT03579472

Terminated

M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma
NCT03630809

Terminated

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1

Breast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | HER-2 Gene Amplification | Breast Cancer Female | HER2 Positive Breast Carcinoma | HER-2 Protein Overexpression
NCT05929768

Recruiting

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Early Stage Triple-Negative Breast Carcinoma
NCT00770809

Completed

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Male Breast Carcinoma | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7
NCT03012399

Active, not recruiting

Hypnosedation in Relaxing Patients Undergoing Breast Cancer Surgery

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Prognostic Stage I Breast Cancer AJCC v8 | Prognostic Stage IA Breast Cancer AJCC v8 | Prognostic Stage IB Breast Cancer AJCC v8 | Anatomic Stage 0 Breast Cancer AJCC v8 | Prognostic Stage 0 Breast Cancer AJCC v8
NCT05545150

Active, not recruiting

Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study

Anatomic Stage 0 Breast Cancer AJCC v8 | Prognostic Stage 0 Breast Cancer AJCC v8 | Breast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Bilateral Breast Carcinoma
NCT00637481

Completed

A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer

Breast Cancer | Ductal Breast Carcinoma in Situ | Atypical Ductal Breast Hyperplasia | Lobular Breast Carcinoma in Situ
NCT07597642

Not yet recruiting

ON-treatment Single-cell Analysis for the Identification of Early Tumor Response Biomarkers on Prospective Collected Serial Tumor Biopsies in Triple Negative Breast Cancer Patient During Standard Neoadjuvant Chemo-immunotherapy (ONSET)

Breast Cancer Early Stage Breast Cancer (Stage 1-3)
NCT07227038

Recruiting

Living Well With Advanced Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Breast Carcinoma | Metastatic Breast Carcinoma
NCT06998407

Recruiting

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors (AVZO-023-1001)

HR+/HER2- Breast Cancer | HR+, HER2-, Advanced Breast Cancer
NCT06917313

Recruiting

FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

Breast Cancer Early Stage Breast Cancer (Stage 1-3)
NCT06806072

Not yet recruiting

BALNEOTHERAPY FOR BREAST CANCER PATIENTS UNDERGOING ENDOCRINE THERAPY

Breast Cancer Early Stage Breast Cancer (Stage 1-3)
NCT06885671

Not yet recruiting

Single vs Hypofractionated Irradiation For Timely Access to Partial Breast Radiotherapy

Breast Cancer Early Stage Breast Cancer (Stage 1-3)
NCT06733233

Not yet recruiting

A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

HER2 Low Breast Cancer | Breast Cancer, Estrogen Receptor-Positive
NCT06723990

Recruiting

Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX (HER2BREASTDX)

Breast Cancer Early Stage Breast Cancer (Stage 1-3)
NCT06404463

Not yet recruiting

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer (QUEEN-Neo)

Neoadjuvant Therapy | Early Breast Cancer | HR+HER2- Breast Cancer
NCT05959291

Recruiting

Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer (Free-HER)

Stage IV Breast Cancer | HER2-positive Metastatic Breast Cancer
NCT05870813

Recruiting

CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer (CLEAR-B)

Breast Cancer | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer
NCT05774951

Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)

Breast Cancer, Early Breast Cancer
NCT05404321

Recruiting

Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment (TRIPLEX)

Triple Negative Breast Cancer | Organoid
NCT05305937

Not yet recruiting

Implantation of CEST and CESL MRI Methods for Detection of Breast Tumors

Malignant Tumor of Breast | Benign Breast Lumps | High-Risk Breast Cancer
NCT04573231

Recruiting

Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Breast Cancer | Metastatic Breast Cancer | HER2-negative Breast Cancer
NCT04505826

Completed

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer
NCT07030231

Enrolling by invitation

Use of Intraoperative Radiotherapy in Breast Cancer (RIOMA)

Breast Cancer Early Stage Breast Cancer (Stage 1-3)
NCT04965688

Terminated

Biology Guided Therapy for Breast Cancer for ER Positive (SPOCK)

Breast Cancer | Estrogen Receptor-positive Breast Cancer | HER2-negative Breast Cancer
NCT06472700

Completed

Endoscopic Extirpation of Benign Breast Tumors Using a Lateral Chest Wall Incision

Endoscopic Breast Surgery | Benign Breast Tumors
NCT03911973

Active, not recruiting

Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

TNBC - Triple-Negative Breast Cancer
NCT01471847

Completed

A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Metastatic Breast Cancer (MBC) | Locally Advance Breast Cancer (LABC)
NCT01495247

Terminated

Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer (MBC) | Inoperable Locally Advanced Breast Cancer
NCT02568839

Active, not recruiting

Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer (PREDIX HER2)

Early-Stage Breast Carcinoma | HER-2 Positive Breast Cancer
NCT03761940

Unknown

Health Status of Women With Breast Cancer (OSTaRa)

Radiotherapy | Breast Conserving Surgery | Women With Early Breast Cancer
NCT04862585

Completed

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8
NCT07465523

Recruiting

A Novel Approach in the Evaluation of Breast Masses With Doppler US

Breast Neoplasm Female | Benign Breast Neoplasm | Malign Breast Neoplasm | Doppler Ultrasound Diagnosis
NCT03391388

Active, not recruiting

3D-CRT, Proton, or Brachytherapy APBI in Treating Patients With Invasive and Non-invasive Breast Cancer

Estrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast Carcinoma
NCT07581314

Not yet recruiting

Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)

Triple-Negative Breast Cancer (TNBC) | Metastatic Triple-negative Breast Cancer | Advanced Triple-Negative Breast Cancer
NCT05333328

Recruiting

OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk (INTERSTELLAR)

Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive Tumor | Premenopausal Breast Cancer | Node-positive Breast Cancer

Clinical Trials on Glabellar Crease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations